

Voyageur Pharmaceuticals Announces Appointment of Ethan Mohan as Executive Vice President

written by Raj Shah | May 12, 2025

May 12, 2025 ([Source](#)) – Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”) a radiology contrast media company focused on vertical integration and secure supply chains, is pleased to announce the appointment of Ethan Mohan as Executive Vice President of Voyageur, subject to regulatory approval. Mr. Mohan’s appointment is a promotion from his previous position of Sales Manager of Voyageur and marks another strategic advancement in the Company’s leadership team as it continues to move towards the establishment of a sales presence.

Mr. Mohan has been a pivotal force behind forging Voyageur’s sales strategies and strategic partnerships that have set the stage for the Company’s market presence. Since joining Voyageur, Mr. Mohan has consistently demonstrated exceptional leadership, strategic foresight, and operational expertise, along with an unwavering commitment to advancing the Company’s vision of becoming a global leader in the radiographic contrast agent market.

As Executive Vice President, Mr. Mohan will take on an expanded role overseeing corporate strategy, business development, and international market expansion initiatives, while continuing to champion Voyageur’s mission of delivering high-quality, sustainable barium and iodine-based products to the global healthcare market.

“Ethan’s promotion marks an important milestone for Voyageur as we enter a transformative phase in our growth,” said Brent Willis, CEO of Voyageur. “Ethan brings a rare combination of scientific expertise and entrepreneurial acumen that we expect will directly lead to the development of commercial success for Voyageur. His leadership has positioned the Company to be in a position to capitalize on emerging global opportunities. As we move forward with the development of Frances Creek, navigate FDA regulatory pathways, and scale our international footprint, Ethan’s strategic insight and executional drive will be critical to propelling Voyageur into its next phase of expansion.”

Mr. Mohan added: “It is a privilege to step into the role of Executive Vice President at such a pivotal time in Voyageur’s evolution. As global demand for contrast media accelerates, expected to reach \$12.6 billion by 2032 (<https://www.grandviewresearch.com/industry-analysis/contrast-media-contrast-agents-market>), management of Voyageur believes it stands alone as the only contrast media company with fully integrated, scalable resource-to-ready solutions capable of directly mitigating this global supply crisis.

Voyageur believes its steadfast commitment to the development of barium and iodine-based contrast agents will position it to lead the market with a portfolio that is not only sustainable and cost-efficient, but purpose-built to elevate standards of care worldwide. By delivering high-quality, affordable contrast media, Voyageur aims to ease the burden on healthcare systems and enhance patient outcomes globally. I am proud to be part of an organization that I believe is not just responding to market needs, but reshaping the future of diagnostic imaging through innovation, execution, and purpose-driven growth. We extend our sincere gratitude to our strategic partners and shareholders for their resolute commitment as we continue to strive to achieve **significant** milestones in our commercial development.”

The Company congratulates Mr. Mohan on this well-deserved promotion and looks forward to his continued contributions as a member of the senior executive team.

About Voyageur Pharmaceuticals Ltd.

Voyageur, a Canadian public company trading under the symbol VM on the Exchange, is in development of barium and iodine Active Pharmaceutical Ingredients (API) that offer high-performance and cost-effective imaging contrast agents. With a strategic focus on vertically integrating the barium and iodine contrast markets, Voyageur aims to become a key player by producing its own barium and iodine. In addition, Voyageur is pursuing the development of new endo fullerene drugs.

Voyageur's business plan is set to generate cash flow by partnering with established third-party GMP pharmaceutical manufacturers in Canada thereby ensuring the validation of its products by regulatory agencies worldwide. As Voyageur solidifies its presence in the market, it plans to transition into a high-margin domestic manufacturer of radiology drugs.

Voyageur is committed to sustainability and environmental stewardship. Voyageur envisions a future where reducing carbon emissions is the norm, and to achieve this, it intends to build state-of-the-art carbon-capture infrastructure utilising the Rain Cage *EDENTM* system. By investing in carbon capture energy sources and sustainable manufacturing practices, Voyageur aims to generate revenue from carbon captured "advanced carbon production". Voyageur believes its unwavering commitment to the environment sets it apart as a pioneer in the industry.

At the core of its operations, Voyageur owns a 100% interest in the Frances Creek barium sulphate (barite) project. Currently, the world's pharmaceutical barium sulphate is almost entirely

synthetically produced resulting in a less effective imaging quality product. Voyageur's Frances Creek resource boasts a rare and exceptional grade mineral suitable for the pharmaceutical marketplace that Voyageur believes will replace the current synthetic products with higher quality imaging products.

Voyageur's ambitious vision is to become the first vertically integrated company in the radiology contrast media drug market. By controlling all primary input costs, from the sourcing of raw materials to final production, Voyageur believes it can ensure quality and cost efficiency. With its approach, it embodies the motto of "From the Earth to the Bottle," highlighting Voyageur's commitment to responsible sourcing and manufacturing practices.

For Further Information:

Brent Willis, CEO,	Albert Deslauriers, CFO,
Brent@vpharma.ca, 403-923-5944	Albert@vpharma.ca
info@vpharma.ca	https://voyageurpharmaceuticals.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Statement Regarding "Forward-Looking" Information

This news release may contain certain forward-looking information and statements, including without limitation, statements pertaining to: regulatory approval of Ethan Mohan's appointment as Executive Vice President of the Corporation and Voyageur's business plans. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information

will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in the Company's disclosure documents on the SEDAR+ website at www.sedarplus.ca. Voyageur does not undertake to update any forward-looking information except in accordance with applicable securities laws.